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besity and the Heart
Weighty Issue*
tephan von Haehling, MD,†
olfram Doehner, MD, PHD,‡
tefan D. Anker, MD, PHD†‡
ondon, United Kingdom; and Berlin, Germany
besity has been recognized as an important risk factor that
ontributes to the development of many different disease
tates worldwide. The World Health Organization (WHO)
as implemented a definition that subjects with a body mass
ndex (BMI) of 25 kg/m2 or above should be diagnosed as
verweight and those with a BMI of 30 kg/m2 or greater as
bese (1). The WHO states that obesity is one of the most
latantly visible, yet most neglected, public health problems.
ecent data suggest that the waist-to-hip ratio may even
etter predict cardiovascular illnesses than BMI (2). The
revalence of overweight in the U.S. is increasing in recent
ears with 64.5% of the adult population being overweight
nd 30.5% being obese (3). These figures have led comedian
nd television host Jay Leno to observe that “. . . there are
ore overweight people in America than average-weight
eople. So overweight people are now average” (4). And
here may be some truth in this statement.
See page 2267
The problem of obesity is not restricted to the U.S., and
he prevalence of overweight is increasing at an alarming
ate worldwide. The International Obesity Task Force has
stimated that at present at least 1.1 billion adults are
verweight (5). The risk of developing diabetes, hyperten-
ion, or dyslipidemia starts to increase from a BMI of as low
s 21 kg/m2 (5). The rise in the plasma level of low-density
ipoprotein in obese patients leads to an increase in the risk
f coronary artery disease by a factor of 3.6 (5), and
pproximately 50% of cases of hypertension are secondary to
besity (6).
The prevalence of obesity in children and adolescents is
apidly growing as well. The presence of the perturbation at
his age appears to program adult obesity (7). Risk factors
uch as obesity during childhood and the duration of
xposure lead to premature signs of cardiovascular disease
6). Indeed, obesity leads to a number of structural changes
f the myocardium. Obesity-related hypertension and ele-
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †National Heart and Lung Institute, Department of Clinical Cardiology,
mperial College School of Medicine, London, United Kingdom; and the ‡Divisionp
f Applied Cachexia Research, Department of Cardiology, Charité Medical School,
ampus Virchow-Klinikum, Berlin, Germany.ated blood viscosity yield growth of the cardiac wall and
hus induce concentric left ventricular (LV) hypertrophy (8).
f hypertension is absent, the heart may also be harmed by
hronic volume-overload as a consequence of an elevated
ardiac output. Thus, LV dilation and LV hypertrophy are
lso common in normotensive patients (9).
In this issue of the Journal, Chinali et al. (10) have
nvestigated the impact of obesity on cardiac geometry and
unction in a population of adolescents from the Strong
eart Study (SHS). The SHS is a trial of cardiovascular
isease and its risk factors among American Indian men and
omen (11). It was set up in 1988 as the largest epidemi-
logic study of American Indians ever undertaken. The
HS trial was designed to estimate cardiovascular mortality
nd morbidity and to determine cardiovascular disease risk
actors in American Indians (11). A total of 13 American
ndian tribes and communities in three geographic areas
ere included. Three different substudies were undertaken,
nd a total of 4,500 tribal members age 45 through 74 years
ere clinically examined for the original study between 1993
nd 1995. The participants are being followed up to the
resent day. An additional substudy was started between
001 and 2003. As part of this substudy of SHS, a total of
60 unselected adolescent participants age 14 through 20
ears were enrolled.
In the adolescent population from the SHS trial investi-
ated by Chinali et al. (10), LV mass as assessed by
chocardiography was 132  30 g in normal weight, 149 
7 g in overweight, and 165  41 g in obese subjects (both
 0.05 vs. normal weight). Not surprisingly, LV hyper-
rophy was more common in obese (33.5%, p  0.05 vs.
ormal weight) than in overweight (12.4%, p  0.05 vs.
ormal weight) and normal weight (3.5%) participants. The
troke volume was 79.5  12.8 ml in obese participants and
hus increased (p  0.05 vs. overweight and normal weight)
ompared with both normal weight (73.1  10.4 ml) and
verweight participants (76.5  10.8 ml) indicating in-
reased cardiac workload.
These findings are in line with earlier reports from other
thnic groups. The Bogalusa Heart study (12), for example,
howed that there is a strong association between LV mass
n childhood and young adults across BMI quartiles in both
hites (n  334) and blacks (n  133). Linear regression
nalysis showed a strong relationship between the degree of
besity and LV mass (r  0.52, p  0.001). Moreover, this
tudy demonstrated that obesity in childhood significantly
redicts LV mass in adulthood (12). Another multiethnic
tudy in 46.5% white, 38.0% black, and 15.5% Hispanic
hildren and adolescents age 4 to 22 years found similar
esults (13). In the latter population, 41% were diagnosed
ith LV hypertrophy. Children with LV hypertrophy were
ore likely to be overweight than those without (odds ratio
.02, 95% confidence interval 2.17 to 11.61, p  0.0002)
13). However, LV hypertrophy appeared to be more
revalent in Hispanics than in the other ethnic groups.
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June 6, 2006:2274–6 Editorial CommentChinali et al. (10) note that an increase in LV mass may
o some degree result from an increased hemodynamic
orkload. Hence, it may represent a physiologic response of
he cardiovascular system. This explanation does not ac-
ount for the disproportional further LV hypertrophy in
bese subjects. In such patients, pathophysiological vicious
ircles are being activated that lead to maladaption of the
yocardium. Indeed, not only structural but also functional
arameters are being hampered in obesity. The mechanisms
nderlying this finding deserve closer scrutiny, as they shed
ight on a shifting paradigm of cardiovascular pathophysi-
logy. Our understanding has shifted away from a mere
emodynamic disorder to a broader approach involving
ormonal metabolic and immunologic derangements (14).
n this context, increasing insulin resistance might be of
ivotal importance. Unfortunately, the study by Chinali et
l. (10) did not evaluate associations between insulin resis-
ance parameters and echocardiographic assessments.
Insulin is one of the most powerful protein-anabolic
ormones and controls a multitude of pathways beyond
lucose control. Hyperinsulinemia may play an important
art in the development of myocardial hypertrophy. This
ay also be regarded as an early aspect of the development
f diabetes-associated cardiomyopathy that may ultimately
ield chronic heart failure (CHF) (14). Obesity-related
ncreases in fatty acids impair glucose utilization in a
etabolic cycle that involves imbalanced substrates for
nergy metabolism (15). The resulting insulin resistance
ccounts for a variety of effects including but not limited to
ncreased oxidative stress, immune activation, tissue fibrosis,
nd impaired microvascular homeostasis, all of which con-
ribute to the heart failure syndrome (14,16). Only recently,
nsulin resistance received increasing attention as part of the
evelopment and progression of CHF: it impacts on pa-
ients’ symptomatic status and represents an independent
arker of impaired survival (17).
Chinali et al. (10) suggest that metabolic derangements
ay contribute to myocardial abnormalities. Thus, CHF
ay develop independent of hemodynamic impairment
rom hypertension or ischemia. However, it is interesting to
ote that obesity, other than involuntary weight loss or
achexia, shows beneficial prognostic associations once
HF has developed. Cachexia is a well-recognized risk
actor and an independent predictor of impaired survival in
dvanced CHF (18,19). In a study in 525 unselected
onsecutive CHF patients without evidence of weight loss
ho were subdivided according to ascending quintiles of
MI, on the other hand, survival was greatest among those
n the fourth quintile with a mean BMI of 29.2 0.8 kg/m2
20). Thus, obesity leads to metabolic and myocardial
hanges that may trigger the development and the progres-
ion of CHF. But patients with CHF, who have a poor
rognosis per se, appear to benefit from being overweight.
The most intriguing question in this respect is to define
time point after which obesity does not pose as a risk factor
nymore. Indeed, data from patients after complicatedyocardial infarction in the Optimal Therapy In Myocar-
ial infarction with the Angiotensin II Antagonist Losartan
OPTIMAAL) (21) and retrospective data from 22,666
atients undergoing coronary artery bypass grafting with or
ithout valve surgery (22) suggest that a higher body weight
s beneficial once cardiovascular disease is present (Fig. 1).
or young people with presence of established risk factors
or future cardiovascular illness (like hypertension, hyper-
ipidemia or diabetes), it seems very likely that obesity
onfers a somewhat higher risk for death compared to
eople with normal weight. Whether the same is true for
lder people is not known. We hypothesize that obesity
arries no adverse mortality impact above the age of 60
ears—possibly even from age 55 to 50 years. This remains
o be tested.
eprint requests and correspondence: Prof. Stefan D. Anker,
harité Medical School, Campus Virchow Klinikum, Division of
pplied Cachexia Research, Augustenburger Platz 1, 13353 Ber-
in, Germany. E-mail: s.anker@cachexia.de.
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